{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:52:47Z","timestamp":1791395567710,"version":"4.3.3"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Solid tumors account for about 30% of all pediatric cancers. The diagnosis is typically based on histological and molecular analysis of a primary tumor biopsy. Liquid biopsies carry several advantages over conventional tissue biopsy. However, their use for genomic analysis and response monitoring of pediatric solid tumors is still in experimental stages and mostly performed retrospectively without direct impact on patient management. In this case series we discuss six clinical cases of children with a solid tumor for whom a liquid biopsy assay was performed and demonstrate the potential of liquid biopsy for future clinical decision making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed quantitative real-time PCR (RT-qPCR), droplet digital PCR (ddPCR) or reduced representation bisulphite sequencing of cell-free DNA (cfRRBS) on liquid biopsies collected from six pediatric patients with a solid tumor treated between 2017 and 2023 at the Princess M\u00e1xima Center for Pediatric Oncology in the Netherlands. Results were used to aid in clinical decision making by contribution to establish a diagnosis, by prognostication and response to therapy monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In three patients cfRRBS helped to establish the diagnosis of a rhabdomyosarcoma, an Ewing sarcoma and a neuroblastoma (case 1-3). In two patients, liquid biopsies were used for prognostication, by MYCN ddPCR in a patient with neuroblastoma and by RT-qPCR testing rhabdomyosarcoma-specific mRNA in bone marrow of a patient with a rhabdomyosarcoma (case 4 and 5). In case 6, mRNA testing demonstrated disease progression and assisted clinical decision making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case series illustrates the value of liquid biopsy. We further demonstrate and recommend the use of liquid biopsies to be used in conjunction with conventional methods for the determination of metastatic status, prognostication and monitoring of treatment response in patients with pediatric solid tumors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1209150","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T05:27:20Z","timestamp":1692336440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring"],"prefix":"10.3389","volume":"13","author":[{"given":"Nina U.","family":"Gelineau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Barneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atia","family":"Samim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke","family":"Van Zogchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Matser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies M. C.","family":"Mavinkurve-Groothuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"van Grotel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3szef","family":"Zsiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K. A.","family":"van Eijkelenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger R. G.","family":"Knops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelof","family":"van Ewijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin P. S.","family":"Langenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald De","family":"Krijger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Hiemcke-Jiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Van Paemel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Cornelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katleen","family":"De Preter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"De Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Van Der Schoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godelieve","family":"Tytgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/jpdn.2003.12","article-title":"Solid tumors in children","volume":"18","author":"Kline","year":"2003","journal-title":"J Pediatr Nurs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205173","article-title":"Intra-tumour genetic heterogeneity and prognosis in high-risk neuroblastoma","volume":"13","author":"L\u00f3pez-Carrasco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010079","article-title":"Genetic and histopathological heterogeneity of neuroblastoma and precision therapeutic approaches for extremely unfavorable histology subgroups","volume":"12","author":"Shimada","year":"2022","journal-title":"Biomolecules"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26870-z","article-title":"Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions","volume":"12","author":"Schmelz","year":"2021","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1586","article-title":"Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma","volume":"24","author":"Chicard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0500","article-title":"Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma","volume":"22","author":"Chicard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.05.029","article-title":"Intra-tumor genetic heterogeneity in wilms tumor: clonal evolution and clinical implications","volume":"9","author":"Cresswell","year":"2016","journal-title":"EBioMedicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/gcc.22285","article-title":"Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis","volume":"55","author":"Walther","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/0008-5472.CAN-18-1086","article-title":"Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.celrep.2020.01.049","article-title":"Transcriptional programs define intratumoral heterogeneity of ewing sarcoma at single-cell resolution","volume":"30","author":"Aynaud","year":"2020","journal-title":"Cell Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00545-8","article-title":"Paediatric extracranial germ-cell tumours","volume":"17","author":"Shaikh","year":"2016","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1542\/pir.32.7.306","article-title":"Tumor markers in infancy and childhood","volume":"32","author":"Ricafort","year":"2011","journal-title":"Pediatr Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3065","article-title":"New technologies for human cancer imaging","volume":"26","author":"Frangioni","year":"2008","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00285","article-title":"Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors","volume":"2018","author":"Klega","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00431-019-03545-y","article-title":"The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review","volume":"179","author":"Van Paemel","year":"2020","journal-title":"Eur J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00046","article-title":"Adjunctive use of circulating tumor DNA testing in detecting pancreas cancer recurrence","volume":"9","author":"Soyano","year":"2019","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes12030349","article-title":"Liquid biopsies: applications for cancer diagnosis and monitoring","volume":"12","author":"Martins","year":"2021","journal-title":"Genes (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27595","article-title":"Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies","volume":"66","author":"Abbou","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605029","article-title":"Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force","volume":"100","author":"Beiske","year":"2009","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.02.003","article-title":"The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma","volume":"47","author":"Stutterheim","year":"2011","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30380","article-title":"Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group","volume":"123","author":"Burchill","year":"2017","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6531","article-title":"PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma","volume":"26","author":"Stutterheim","year":"2008","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.117945","article-title":"Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers","volume":"55","author":"Stutterheim","year":"2009","journal-title":"Clin Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1083","article-title":"Improving risk stratification for pediatric patients with rhabdomyosarcoma by molecular detection of disseminated disease","volume":"27","author":"Lak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080906","article-title":"Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR","volume":"9","author":"Palac\u00edn-aliana","year":"2021","journal-title":"Biomedicines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00130","article-title":"Novel circulating hypermethylated RASSF1A ddPCR for liquid biopsies in patients with pediatric solid tumors","volume":"5","author":"van Zogchel","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B33","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Finklestein","year":"2010","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/sj.bjc.6604887","article-title":"RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker","volume":"100","author":"Misawa","year":"2009","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070959","article-title":"Methylation dynamics of RASSF1A and its impact on cancer","volume":"11","author":"Malpeli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.LiqBiop20-A53","article-title":"Hypermethylated RASSF1A as circulating tumor marker in pediatric and adolescent solid tumors","volume":"26","author":"van Zogchel","year":"2020","journal-title":"Adv liquid biopsies"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1191-5","article-title":"CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA","volume":"18","author":"Kang","year":"2017","journal-title":"Genome Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15592294.2020.1790950","article-title":"Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study","author":"Van Paemel","year":"2020","journal-title":"Epigenetics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13010150","article-title":"Specific and sensitive detection of neuroblastoma mRNA markers by multiplex RT-qPCR","volume":"13","author":"van Zogchel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/PO.19.00261","article-title":"Hypermethylated RASSF1A as circulating tumor DNA marker for disease monitoring in neuroblastoma","volume":"4","author":"van Zogchel","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19076","article-title":"Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma","volume":"8","author":"Lodrini","year":"2017","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3716","article-title":"Targeted analysis of cell-free circulating tumor DNA is suitable for early relapse and actionable target detection in patients with neuroblastoma","volume":"28","author":"Lodrini","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1795","article-title":"Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year","volume":"19","author":"Burchill","year":"2001","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.3604","article-title":"Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1\/SIOPEN study","volume":"32","author":"Viprey","year":"2014","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-0997-x","article-title":"Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma","volume":"137","author":"Y\u00e1\u00f1ez","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1200\/JCO.2003.03.006","article-title":"Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor","volume":"21","author":"Schleiermacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-013-3374-9","article-title":"Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma","volume":"29","author":"Kojima","year":"2013","journal-title":"Pediatr Surg Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.08.006","article-title":"Somatic TP53 mutations are detectable in circulating tumor DNA from children with anaplastic wilms tumors","volume":"11","author":"Treger","year":"2018","journal-title":"Transl Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2647","article-title":"Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed\/refractory neuroblastoma provides a new biomarker for disease and prognosis","volume":"23","author":"Marachelian","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22734","article-title":"Early detection of the PAX3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma","volume":"58","author":"Eguchi-Ishimae","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24268","article-title":"Detection of circulating tumor DNA in patients with osteosarcoma","volume":"9","author":"Barris","year":"2018","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30144","article-title":"Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA","volume":"122","author":"Hayashi","year":"2016","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1758835918774337","DOI":"10.1177\/1758835918774337","article-title":"Precision diagnostics of Ewing\u2019s sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts","volume":"10","author":"Allegretti","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03780-7","article-title":"Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma","volume":"148","author":"Schriegel","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.3390\/cancers13174311","article-title":"Landscape of bone marrow metastasis in human neuroblastoma unraveled by transcriptomics and deep multiplex imaging","volume":"13","author":"Lazic","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0045-3","article-title":"Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information","volume":"31","author":"Koelsche","year":"2018","journal-title":"Mod Pathol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ijc.31620","article-title":"Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis","volume":"144","author":"Jim\u00e9nez","year":"2019","journal-title":"Int J Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2021.09.022","article-title":"The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples","volume":"160","author":"Van Paemel","year":"2022","journal-title":"Eur J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0675","article-title":"Shallow whole genome sequencing on circulating cell-free DNA allows reliable noninvasive copy-number profiling in neuroblastoma patients","volume":"23","author":"Van Roy","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3028","article-title":"Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in ewing sarcoma","volume":"22","author":"Krumbholz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2011.12.002","article-title":"Stability of PCR targets for monitoring minimal residual disease in neuroblastoma","volume":"14","author":"Stutterheim","year":"2012","journal-title":"J Mol Diagnostics"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2287","article-title":"The pediatric cancer genome project","volume":"44","author":"Downing","year":"2012","journal-title":"Nat Genet"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0169-x","article-title":"Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours","author":"Jones","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2020.05.006","article-title":"Assessment of pre-analytical sample handling conditions for comprehensive liquid biopsy analysis","volume":"22","author":"Gerber","year":"2020","journal-title":"J Mol Diagnostics"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1038\/s41467-021-23445-w","article-title":"Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden","volume":"2","author":"Peneder","year":"2021","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0287","article-title":"Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma","volume":"12","author":"Bosse","year":"2022","journal-title":"Cancer Discovery"},{"key":"B69","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.31053","article-title":"Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression","volume":"142","author":"Rifatbegovic","year":"2018","journal-title":"Int J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature14465","article-title":"Human body epigenome maps reveal noncanonical DNA methylation variation","volume":"523","author":"Schultz","year":"2015","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1101\/gr.119867.110","article-title":"A DNA methylation fingerprint of 1628 human samples","volume":"22","author":"Fernandez","year":"2012","journal-title":"Genome Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32361","article-title":"Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma","volume":"145","author":"Bellini","year":"2019","journal-title":"Int J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.077","article-title":"Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma","volume":"21","author":"Cheung","year":"2003","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1089\/152581603322286060","article-title":"Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma","volume":"12","author":"Tchirkov","year":"2003","journal-title":"J Hematother Stem Cell Res"},{"key":"B75","article-title":"Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients","volume":"62","author":"Combaret","year":"2002","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22009","article-title":"Influence of neuroblastoma stage on serum-based detection of MYCN amplification","volume":"53","author":"Combaret","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/pbc.24093","article-title":"Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor","volume":"59","author":"Ohshima","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0849","article-title":"Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma","volume":"18","author":"Stutterheim","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205890","article-title":"Hypomethylation and hypermethylation of DNA in Wilms tumors","volume":"21","author":"Ehrlich","year":"2002","journal-title":"Oncogene"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00113","article-title":"Cell-free DNA as a diagnostic and prognostic biomarker in pediatric rhabdomyosarcoma","volume":"7","author":"Lak","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1209150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T17:48:44Z","timestamp":1692380924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1209150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":80,"alternative-id":["10.3389\/fonc.2023.1209150"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1209150","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"article-number":"1209150"}}